Nicolas Gallastegui

Nicolas Gallastegui

Auto-generated profile, based on publicly available information

Nicolas Gallastegui

Division of Hematology, Department of Medicine, University of Miami Leonard M. Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, FL, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2015 in International Immunology
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
NGNicolas Gallastegui
Nicolas Gallastegui
JRJoseph David Rosenblatt
Joseph David Rosenblatt
Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin’s and non-Hodgkin’s lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.

1 December 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
WZWei Zhao
Wei Zhao
ADAmrita Desai
Amrita Desai
NGNicolas Gallastegui
Nicolas Gallastegui
JRJeremy Ramdial
Jeremy Ramdial
ILIzidore S. Lossos
Izidore S. Lossos
Purpose: Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large cohort of patients, identify risk factors, and determine HGT impact on overall survival (OS). Methods: We analyzed 453 patients with biopsy-proven MZL seen at our institution between 1995 and 2016. Kaplan-Meier, Cox proportional hazards regression, and competing risk methods were used in analyses of time-to-event outcomes. Results: Thirty-four patients (7.5%) had biopsy-proven HGT to diffuse large B-cell lymphoma, including seven (21%) diagnosed at the time of initial MZL diagnosis. Among 27 incident patients, median time to HGT was 29 months (range, 1.3 to 135 months). Higher risk of HGT was observed in those with nodal/splenic MZL (subdistribution hazard ratio [SHR], 2.60; P = .023). On multivariable competing risk analysis, elevated lactate dehydrogenase (SHR, 2.71), more than four nodal sites (SHR, 2.97), and failure to achieve complete remission (CR) after initial treatment (SHR, 3.76) conveyed significantly higher risk for HGT ( P < .02). International Prognostic Index (IPI), Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were only significant predictors of HGT univariably. Patients with HGT had shorter OS (5-year rate, 65% v 86%; P < .001). Patients who presented with HGT within 12 months since MZL diagnosis had shorter OS than those with HGT at MZL diagnosis combined with those with HGT more than 12 months later (4-year rate, 43% v 81%, P < .001). Non-CR and higher scores of IPI, Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were the main significant predictors for shorter progression-free survival and OS. Conclusion: Failure to achieve CR after initial treatment, elevated lactate dehydrogenase, and more than four nodal sites at the time of MZL diagnosis are the main predictors of increased risk of HGT. Patients with HGT have shorter OS.

19 February 2019 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
WZWei Zhao
Wei Zhao
ADAmrita Desai
Amrita Desai
JRJeremy Ramdial
Jeremy Ramdial
NGNicolas Gallastegui
Nicolas Gallastegui
ILIzidore S Lossos
Izidore S Lossos

1 January 2013 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
CACristian Aguilar
Cristian Aguilar
FSFrancisco Socola
Francisco Socola
JDJean A. Donet
Jean A. Donet
NGNicolas Gallastegui
Nicolas Gallastegui
GHGabriel A. Hernandez
Gabriel A. Hernandez
Leiomyosarcomas arising from the wall of blood vessels are rare and aggressive neoplasm. We report a case of a previously healthy 66-year-old woman who presented with intermittent abdominal pain, progressive constipation, and weight loss. Abdominal computed tomography showed a 12 cm solid heterogeneous tumor in the tail of the pancreas. The patient subsequently underwent surgical resection of the pancreatic mass. Surprisingly, histological and immunohistochemical analyses revealed leiomyosarcoma arising from the smooth muscle of the splenic vein. After surgery, she received adjuvant chemotherapy. One year later, there was no evidence of local recurrence. In this paper, we discuss the available information about leiomyosarcomas of splenic vein and its management.

30 September 2015 in Haemophilia
Verified
Journal Article
Closed access
PDF file
NGN. Gallastegui
N. Gallastegui
EKE. L. Kimble
E. L. Kimble
THT. J. Harrington
T. J. Harrington

1 May 2019 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
NGNicolas Gallastegui
Nicolas Gallastegui
RCRyan M. Coe
Ryan M. Coe
ATAlfredo Torres
Alfredo Torres
THThomas J. Harrington
Thomas J. Harrington